Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers
A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
Hepatocellular Carcinoma
Comparing Stereotactic Body Radiation Therapy With Transarterial Chemoembolization in Early-Stage HCC
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
Lenvatinib, Pembrolizumab Combination Promising in Unresectable HCC
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.
Apatinib Significantly Improved Survival in Chinese Patients with Advanced HCC
The administration of apatinib in patients with advanced HCC led to improvements in survival with a manageable safety profile.
Circulating Tumor DNA Levels Linked with Tumor Burden, Survival in HCC
Noninvasive method could help monitor treatment responses.
Intrahepatic T-VEC Injection Plus Pembrolizumab Feasible in HCC, Liver Metastases
Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.
Bevacizumab + Atezolizumab: Survival and Quality-of-Life Benefits in Advanced Liver Cancer Spur Regulatory Approval
Phase 3 clinical trial of combination shows survival and quality-of-life benefits vs the standard of care, sorafenib, leading to the regimen’s expedited regulatory approval.
Immunotherapy Regimen Approved for Hepatocellular Carcinoma
The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Single, Priming Dose of Tremelimumab Plus Durvalumab Active in Second-Line Hepatocellular Carcinoma
Trememlimumab thought to induce immune response.
First-Line Donafenib May Be Superior to Standard of Care in Advanced Hepatocellular Carcinoma
A phase 2/3 trial found that patients with advanced HCC who received donafenib had significantly longer OS compared with sorafenib, the standard first-line therapy.
-
Loading...
-
Loading...
